In Situ Programming of CAR T Cells
Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit. A solution could be to program T cells in vivo. Here, we evaluate the clinical need for in situ CAR T cell programming, compare competing technologies, review current progress, and provide a perspective on the long-term impact of this emerging and rapidly flourishing biotechnology field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Annual review of biomedical engineering - 23(2021) vom: 13. Juli, Seite 385-405 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parayath, Neha N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR T cell therapy |
|---|
| Anmerkungen: |
Date Completed 10.12.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-bioeng-070620-033348 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324179286 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324179286 | ||
| 003 | DE-627 | ||
| 005 | 20231225185749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-bioeng-070620-033348 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324179286 | ||
| 035 | |a (NLM)33863239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parayath, Neha N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Situ Programming of CAR T Cells |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.12.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit. A solution could be to program T cells in vivo. Here, we evaluate the clinical need for in situ CAR T cell programming, compare competing technologies, review current progress, and provide a perspective on the long-term impact of this emerging and rapidly flourishing biotechnology field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR T cell therapy | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a nanoparticle | |
| 650 | 4 | |a off-the-shelf T cell therapy | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Stephan, Matthias T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of biomedical engineering |d 1999 |g 23(2021) vom: 13. Juli, Seite 385-405 |w (DE-627)NLM113497105 |x 1545-4274 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g day:13 |g month:07 |g pages:385-405 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-bioeng-070620-033348 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |b 13 |c 07 |h 385-405 | ||